Advaxis Appoints Dr. Bradley Monk as Lead Cervical Cancer Advisor

PRINCETON, N.J., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced the appointment of Bradley J. Monk, MD, FACOG, FACS as Lead Cervical Cancer Advisor to the Company. Dr. Monk will be leading the development of Advaxis’ Lm Technology™ platform and assisting with the Company’s multiple clinical programs, including those in HPV-associated cancers (cervical, anal, and head and neck), HER2 expressing tumors and prostate cancer.

“Dr. Monk is highly regarded for his clinical research work in gynecologic oncology. His reputation as an international expert in gynecologic malignancies will be an invaluable asset to the Company as we work with the FDA to complete our special protocol assessment review and planned initiation of our Phase 3 AIM2CERV trial in cervical cancer,” said Daniel J. O'Connor, President and Chief Executive Officer of Advaxis. “We are thrilled to formally add Dr. Monk to our team. He will be instrumental in moving Advaxis forward as we continue to advance the clinical development of our three immunotherapy candidates based on our Lm Technology™ platform.”

Dr. Monk brings to Advaxis more than 25 years of experience in medical oncology and clinical research. Notably, he serves as the co-primary investigator of GOG 0265, an ongoing Phase 2 study evaluating Advaxis’ axalimogene filolisbac in patients with persistent or recurrent cervical cancer and remains a key contributor to the development of the AIM2CERV registration program. Dr. David Mauro, who previously served as the Company’s Chief Medical Officer, has moved on to the next opportunity in his career.

Dr. Monk is currently director of the Division of Gynecologic Oncology at St. Joseph’s Hospital and Medical Center. He is also a professor in the Department of Obstetrics and Gynecology at the University of Arizona’s College of Medicine, and at the Creighton University School of Medicine. He is board certified by the American Board of Obstetrics & Gynecology and is a diplomate of the National Board of Medical Examiners.

About Advaxis, Inc.

Located in Princeton, N.J., Advaxis, Inc. is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary Lm Technology™. The Lm Technology™, using bioengineered live attenuated Listeria monocytogenes (Lm) bacteria, is the only known cancer immunotherapy agent shown in preclinical studies to both generate cancer fighting T-cells directed against a cancer antigen and neutralize Tregs and myeloid-derived suppressor cells (MDSCs) that protect the tumor microenvironment from immunologic attack and contribute to tumor growth. Advaxis' lead Lm Technology™ immunotherapy, axalimogene filolisbac, targets human papillomavirus (HPV)-associated cancers and is in clinical trials for three potential indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The U.S. Food and Drug Administration (FDA) has granted axalimogene filolisbac orphan drug designation for each of these three clinical settings. Advaxis has two additional immunotherapy products: ADXS-PSA in prostate cancer and ADXS-HER2 in HER2 expressing solid tumors, in human clinical development.

For additional information on Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Forward-Looking Statements

This media statement contains forward-looking statements, including, but not limited to: statements regarding Advaxis’ ability to develop the next generation of cancer immunotherapies; and the safety and efficacy of Advaxis’ proprietary immunotherapies. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis’ SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2015, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.

CONTACTS:

Company:
Advaxis, Inc.
Greg Mayes, Executive Vice President and COO
mayes@advaxis.com
609.452.9813 ext. 102

Media Contact:
JPA Health Communications
Catherine Brady
catherine@jpa.com
617-909-0494

Source:Advaxis